202 related articles for article (PubMed ID: 20685223)
21. Therapy of small cell lung cancer with emphasis on oral topotecan.
Pirker R; Berzinec P; Brincat S; Kasan P; Ostoros G; Pesek M; Plāte S; Purkalne G; Rooneem R; Skricková J; Stanculeanu D; Timcheva C; Tzekova V; Zakotnik B; Zielinski CC; Zwitter M
Lung Cancer; 2010 Oct; 70(1):7-13. PubMed ID: 20576312
[TBL] [Abstract][Full Text] [Related]
22. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
23. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
Abraham SA; Edwards K; Karlsson G; Hudon N; Mayer LD; Bally MB
J Control Release; 2004 May; 96(3):449-61. PubMed ID: 15120901
[TBL] [Abstract][Full Text] [Related]
25. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
26. Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention.
Zhigaltsev IV; Maurer N; Akhong QF; Leone R; Leng E; Wang J; Semple SC; Cullis PR
J Control Release; 2005 May; 104(1):103-11. PubMed ID: 15866338
[TBL] [Abstract][Full Text] [Related]
27. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
28. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.
Tardi P; Johnstone S; Harasym N; Xie S; Harasym T; Zisman N; Harvie P; Bermudes D; Mayer L
Leuk Res; 2009 Jan; 33(1):129-39. PubMed ID: 18676016
[TBL] [Abstract][Full Text] [Related]
29. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
30. [Combination chemotherapy of HO-221, a derivative of benzoylphenylurea with various anticancer agents against human cancer xenografts in nude mice].
Fujita F; Fujita M; Inaba H; Sugimoto T; Okuyama Y; Taguchi T
Gan To Kagaku Ryoho; 1991 Oct; 18(13):2263-70. PubMed ID: 1929447
[TBL] [Abstract][Full Text] [Related]
31. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
32. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
[TBL] [Abstract][Full Text] [Related]
33. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
Patel KJ; Trédan O; Tannock IF
Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
[TBL] [Abstract][Full Text] [Related]
34. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
[TBL] [Abstract][Full Text] [Related]
35. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model.
Wong MY; Chiu GN
Nanomedicine; 2011 Dec; 7(6):834-40. PubMed ID: 21371568
[TBL] [Abstract][Full Text] [Related]
36. Development of a highly stable and targetable nanoliposomal formulation of topotecan.
Drummond DC; Noble CO; Guo Z; Hayes ME; Connolly-Ingram C; Gabriel BS; Hann B; Liu B; Park JW; Hong K; Benz CC; Marks JD; Kirpotin DB
J Control Release; 2010 Jan; 141(1):13-21. PubMed ID: 19686789
[TBL] [Abstract][Full Text] [Related]
37. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
[TBL] [Abstract][Full Text] [Related]
38. In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors.
Leonetti C; Scarsella M; Semple SC; Molinari A; D'Angelo C; Stoppacciaro A; Biroccio A; Zupi G
Int J Cancer; 2004 Jul; 110(5):767-74. PubMed ID: 15146568
[TBL] [Abstract][Full Text] [Related]
39. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
40. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D
Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
